Mr. Speaker, if the gentleman would yield, why do you not do the charts because I think it is always the most informative for our audience. Mr. Speaker, I thank my colleague from Minnesota. As that chart shows, basically the difference…
Mr. Speaker, if the gentleman would yield, why do you not do the charts because I think it is always the most informative for our audience.
Mr. Speaker, I thank my colleague from Minnesota.
As that chart shows, basically the difference between the United States price for the same drugs, same name-brand products from Germany to Canada to England is in the United States our seniors and our citizens have to pay somewhere between 40 to 60 percent more for the same drugs they would get at their pharmacy than their G-8 or other members of the European Union; and you and I have done this many times, and the fact is we are not talking about some field somewhere in some mythological moment of some dream. There is parallel trading today in Europe.
If you go to a pharmacy in Germany, they will price out that product you need, whether it is Lipitor, for whatever you need Lipitor for, the cholesterol, whether you need another drug for blood pressure, for arthritis, or for your heart. Any of those medications they will look at Spain, look at England, they will find the best price for you, and all we are talking about is having the American consumers, our senior citizens, link into that free market, get the competition on price. So rather than paying 50 to 60 percent more than what people in England pay for Lipitor, we would pay the price that they pay in England or in Canada or in Italy or in the Netherlands or in Germany or in France.
It is ironic because all those folks from those countries come to the United States for our medical care. Yet Americans must go overseas for their medications, and what we are talking about is having a system where you bring real competition to the pricing of pharmaceutical products and allow that competition and that market to bring the prices down and allow that choice to exist, not so people would have to drive up to Canada, not so people would have to go on the Internet to get their pharmaceutical products; but that the prices that the people are now paying in Canada and in Germany and France for Tamoxifen, for Cipro, I am trying to look at the drugs, my eyes are not as good as they used to be, Zokor, those prices would come to their local pharmacy. They would go right down the street and get those prices, go to the pharmacist who would say, well, I think I can get something better in Toronto for you, or, we have the same price right here.
That competition would bring the prices down here; and that is all we are talking about, and every product, whether that is in steel, autos, electronic, software, food, America has the most open markets and the best prices in the world. There is only one product line where we have a closed market, and that is the pharmaceutical products; and it is the only product that Americans pay 30, 40, 50, depending on the product, sometimes 60 percent more than our European allies and Canada.
I would like to give you two other statistics. According to Families USA, of the 50 drugs most commonly used by seniors, the prices have increased 3\1/2\ times the rate of inflation over the past year; and between 2000 and 2003, seniors' expenditures on prescription drugs increased by 44 percent. So drug prices are going up.
We have now got a prescription drug bill that offers seniors no benefit as relates to price and affordability of those drugs, and now they are going to continue to go up; and unless we bring something that brings competition and choices to the system, the seniors are going to continue to pay somewhere north of 15 percent increases in prices, and our taxpayers are going to be funding not $400 billion, but close to $600 billion in a prescription drug benefit when we know we can get the prices of these drugs much cheaper.
I see you have the next chart. That is why I wanted to bring these statistics.
Mr. Speaker, I am glad you pointed that out. In each of those years pharmaceutical products ran higher in the sense of inflation by the average of 5 to 6 percent more than the core inflation rate.
Thank you. Five to six times more than the core inflation rate, and it is what drives seniors. I have done town halls, but also I still do office hours at grocery stores and pharmacies where I just meet constituents; and seniors always tell you, I cannot afford the drugs I need. There is an issue of price.
The second issue they said, do not harm the plan I have. I have a good plan from where I work; please do not harm it.
Lastly, and in this order basically, they would then say can we not get a benefit under Medicare, and in the bill that was just passed here and the reason I opposed it is on the fundamental issue of price and affordability.
The legislation on prescription drugs was totally silent on dealing with price. And what we have proposed here, your legislation, deals with the issue of price and affordability and allowing pharmaceutical products and allowing Americans to get the products they need at world- class prices, that is, at 50 percent discount, 40 percent discount, and what people in Germany, France, England, Canada, Italy, the Netherlands, or Ireland is paying. That is what we are trying to do, is address the issue of price and affordability that all of our seniors have talked about.
Then it brings up the other issue. If we are going to have this benefit as part of Medicare, whether our taxpayers today or our children tomorrow pay for it, to me it is mind-boggling why, when you know that you could get prices cheaper for the same brand-name drug, Lipitor or Zocor, why you would get those drugs and pay 40 percent more when you know you can get them 40 percent cheaper. Any CEO who told their board, look, we have checked it out, our supplier, we can get a better price, 40 percent better, but we are going to take a pass on it, that CEO would be fired.
We as the stewards of the taxpayers as well as our senior citizens have an obligation if we know we can get that same drug, that same product for 40 percent less, we have an obligation to do that.
Eventually, we are going to turn our time to the issue of safety, but Health and Human Services is spending $80 million on a commercial to convince people the prescription drug bill they passed was a good bill. For about $80 million we could literally put in place, the Food and Drug Administration, a safety plan so that when people bought their drugs in Canada, Europe, et cetera, they could know for sure that they were safe.
Today, not a single drug, in the last 10 years, has anybody ever gotten sick from buying drugs from Canada. We know that for a fact. But for the same amount of money that they are using to try to persuade people that what we did was good, we could put a safety program in place and allow the free market to operate the way it is supposed to operate.
Right. First of all, 2 years ago is the last year for which we have data, and the data shows that the United States imports $15 billion, just shy of $15 billion a year of pharmaceutical products into the country. $15 billion. We already do it.
Lipitor used to be manufactured in western Michigan. Today, Lipitor, a drug that some of our colleagues use, we know the Vice President of the United States uses, we know the Secretary of Health and Human Services uses, is now manufactured in Ireland.
Every tablet is manufactured in a facility not in the United States. It used to be here, but it is manufactured in Ireland. Then it is exported, same packaging, to the pharmacy shops in France, Germany, England, Ireland, United States, Canada, and around the world. Yet that drug, Lipitor, we pay 50 percent more in the United States than they do in Canada for Lipitor. It is the number one selling drug for senior citizens with high cholesterol.
I thank my colleague, Mr. Speaker.
The reason I brought up the $80 million being dedicated towards advertising the prescription drug legislation and that for that same amount of money we could put in place a system at the Food and Drug Administration to ensure that people could buy their drugs safely is because President Kennedy once said, ``to govern is to choose;'' and that is the choice we have made.
With that system in place, we would have, as the gentleman said, rather than having specifically a benefit that some do not think accomplishes that much, we would bring the discounted prices, the 40 percent retail discount price, right to our pharmacies in the United States and to our consumers,
saving billions of dollars throughout the health care system that could be dedicated towards the uninsured, towards whatever we wanted to dedicate it to. It would literally wring out an inefficiency in the health care system by allowing the, irony of ironies, the free market to work.
Secondly, we know from the Wall Street Journal, I think about 3 months ago, that the pharmaceutical industry thought that the best way to defeat this legislation was to scare people by talking about people getting sick, the safety risk of the pharmaceutical drugs imported from Canada. Yet in sworn congressional testimony, the Food and Drug Administration acknowledged not one person they could find has ever gotten sick from buying drugs from Canada and Europe, and yet 2 million Americans do it every year. People have gotten sick from food that has been imported from around the world, but not one person who bought their drugs from Canada has ever gotten sick, according to the Food and Drug Administration, and close to 2 million Americans do it a year.
So that is number one.
Number two, in my State, my governor conducted a study looking at the likelihood if they were to import medications from Canada how much they could save Illinois. We spend close to $350 million a year for retirees and State employees. The State would save its taxpayers $91 million if they bought their drugs competitively. In addition to that, and the New York Times acknowledged this about the study, the study in Illinois found that Canada actually had a safer system than the United States because less people touch the drug from manufacturing to the shelf in the pharmacy.
So this whole notion of fear was literally an embellished story by the pharmaceutical industry as a way to defeat this legislation. And what I am proud of is that not only the American people have not bought it, but 243 Members of our colleagues here in this hall did not buy it, passed this legislation this year not once but twice, and, hopefully, the other body, the other Chamber will follow suit. This whole notion of safety was a red herring by the industry to intimidate people.
I will make one last comment about safety. Six years ago, when the generic industry was just being started, the name-brand pharmaceutical industry said the problem with generics was safety. What did we discover? We discovered that a lot of those generic pills were being manufactured at the same facilities that the brand-named drugs were being manufactured at. Then they walked away from the safety argument, and generics have grown as an industry, saving tens of billions of dollars for our consumers.
They left that argument on the shelf, but when it came to competitive pricing for pharmaceutical products, which allow the market to work, which the gentleman's legislation does, they brought up the safety issue. And, once again, we have shown in sworn testimony where the FDA says not a single person has ever been recorded getting sick, and the American consumers have not bought that argument that the industry has tried to scare them with. They know they can do. They do it every year.
My colleague and I run into seniors every year, I run into them at some of the public housing and some of the other senior housing in my district, where somebody on the haul will get everybody's prescription and will go up to Canada, fill everybody's prescription, and come back. They know it is normal. They do not think anything is wrong with this. They just cannot understand why we cannot do it here.
So on that issue I wanted to address those specific points on safety, and I yield back to my colleague.
The gentleman and I have talked about this. What galls me a little about this whole subject is that not only are we paying the most expensive prices in the world but all the research that the pharmaceutical industry does is subsidized by the taxpayers. They write it off fully, 100 percent. The taxpayers are literally funding the research. Not only do we fund the research for this new medication, we have the dubious honor to pay the most expensive prices in the world. Second, is through the National Institute of Health, which is an annual budget here in the Federal Government of $27 billion, not all of it going to research for new medications, yet all the primary research that they do, I think it is about half of it, literally is subsidized by the taxpayers. One cannot think of a cancer drug or an AIDS drug, just to name two, that the taxpayers did not do the primary research. The pharmaceutical industry took that research, took it to market, took it through stages one and two, but the primary research was paid for by the taxpayers directly through the National Institutes of Health and then the follow-on research was subsidized through the tax credit research and development.
All the R&D that the companies do is tax free, the taxpayers subsidize it; and then we pay the highest prices at our pharmacies for those same drugs that a lot of these companies sell on the shelf in Canada, in England, in France, in Germany for 40 percent to 60 percent less.
So we paid for the research and then we pay the highest prices in the world. The gentleman noted that. That to me is what is most galling here. I do not fault really the pharmaceutical industry. I fault us here in the political system who have a job to represent our taxpayers, our middle-class families, our seniors, for allowing them to get away with a system that manipulates the patent laws, deals with tax subsidies through the NIH or through the tax credit R&D, and then passes legislation that literally gets away without dealing with the fundamental issue that all of us have constantly heard about at our town halls, at our grocery stores and at our pharmacies and, that is, we cannot afford the medication we need. It is not that they needed a benefit, not that a benefit was a bad thing to do, but they wanted the medications they needed at the prices they can afford.
I give the pharmaceutical industry credit for two things: one, they played the system perfectly, and I do not fault them; second is that they do good work. I was once in the hospital for 7\1/2\ weeks. I would not be here if it were not for some of the products that they had developed. I have no problem with that. But the prices I paid at the hospitals were a lot cheaper than what we pay at the pharmacies.
All we are asking for is that same competition to get those prices. We are prevented from doing it. This legislation that was recently passed specifically outlaws it; and I do believe, as I do in free markets, that if you allow that competition and you allow the consumer that freedom, you are going to get choice. Once that choice gets into the market, prices will come down here. Let me say, they will go up in Europe. But you will have an equilibrium, and you will not have a 50 percent disparity where we end up subsidizing those folks in Europe. When I say ``we,'' hardworking middle-class families, taxpayers and the senior citizens.
I say pay for the research, I want us to own that research, but we need not have to pay the highest prices in the world. That is the mistake. The prices on the shelf at the pharmacies, that is the error here. We can do something about it. We have done it here in the House. Hopefully, our colleagues in the other body will also follow suit.
Before I leave, I wanted to add one other point. I think the gentleman explained this, and I had not even known this, but on Tuesday night, the pharmacies across America get the new prices coming in over their fax machines. Going to that other chart, this year we are expecting pharmaceutical products will go up 18 percent. Inflation will be at 2 percent. So if you go to your pharmacy, to all the people who may be watching, and you go to fill your prescription, then you wonder why the same prescription that 3 months ago if you get a 3-month supply or a month ago cost 21 bucks or 50 bucks and this month, the same drug, nothing changed, nothing, but it is up $12, it is all because of that chart.
You can go ask your pharmacist if you have time on your hands on Wednesday how much they priced up all the products. Unfortunately, what the pharmaceutical companies have done, we just talked about it, they game the tax laws. Again, no criticism, but they have gamed the patent laws in this country, they are gaming the legislation on prescription drugs, and what they decided to do was price up the pharmaceutical products right before this discount card is introduced. So what it is going to look like is a sale at Neiman Marcus around America, which is rather than paying and getting, quote-unquote, this 25 percent discount, which I am not really sure will ever materialize, what you are really going to see is a run-up in prices right before this summer, and you are seeing it today at your pharmacy. So if your prices are going up, you know what is going on, and when this big balloon, big announcement is going to happen, you are going to see a big sale at Neiman Marcus right here in America. You are not going to get a sale price. They are just plussing it up before the big discount card. Our American senior citizens are going to be running around in a cul-de-sac chasing themselves, and there is going to be no discount, the taxpayers are going to be saddled with a big bill, they are going to pay $35 a month for this card, and they are going to see no discount.
Yet we literally have in front of us the opportunity, and the gentleman noted a figure, I think it is an accurate figure, at a minimum, to save $60 billion this year if we had competition in the free market. That could go toward other things in our system, a college education, buying things for kids' education, other type of health care needs; but it just could be so much more productive than what we are doing with it. I think it is so important that we pass this legislation so that the legislation we do pass finally deals with the central issue our constituents tell us about, price and affordability, and so we do not have to hear the story about a mortgage consultant doing reverse mortgages for our senior citizens so they can literally take the equity out of their homes so they can buy their medications that they need.
This is the greatest country in the world. We are all fortunate to live here. We can do better than what we have just seen in front of us. I thank the gentleman for taking this time to organize this.